Human endometrium has the remarkable ability to regenerate all cellular compartments with every menstrual cycle; the cellular source remains unknown. The objective of the present study was to determine whether the bone marrow (BM) is a source of multiple endometrial cell types using a murine BM transplant model. BM cells were harvested from transgenic donor mice that ubiquitously express green fluorescent protein (GFP) and were injected into lethally irradiated, syngeneic female recipient mice. Recipients with successful hematopoietic reconstitution were sacrificed at 3, 5, 9, and 12 mo posttransplant, after which hysterectomy was performed. Numbers of GFP-positive, CD45-positive, and CD45-negative cells in the endometrial stromal and epithelial compartments were determined. In the stromal compartment, BM-derived cells (BMDCs) were detectable as early as 3 mo posttransplant, and the BM remained a long-term contributor of nonhematopoietic endometrial cells. Nonhematopoietic endometrial cells comprised 47.3%-72.2% of total BMDCs in the stromal compartment at 12 mo posttransplant. In contrast, BMDCs were not detected in the glandular or luminal epithelial compartments until 12 mo posttransplant. These data demonstrate that the BM is a significant source of nonhematopoietic endometrial stromal compartment cells and contributes to a much lesser extent to the epithelial compartments. That BM is a source of nonhematopoietic cells in the endometrial stromal and epithelial compartments provides a potential mechanism by which monthly regeneration of the endometrium may occur. bone marrow, endometrial stem cells, endometrium, murine bone marrow transplant
INTRODUCTION
Human endometrium is a dynamic tissue comprised of two zones: 1) the functionalis, which is a transient layer containing the glandular and luminal epithelium as well as the supporting stroma; and 2) the basalis, which is comprised of the basal regions of the glands and stroma, supporting vasculature, and lymphoid aggregates. Replenishment of all cellular compartments of the endometrial functionalis layer with each menstrual cycle is absolutely essential for normal human reproductive function. Despite the significance of this, the mechanisms responsible for cyclic endometrial regeneration are unknown. Evidence suggests that a uterine stem cell population is involved in the cyclic replenishment of the various parenchymal endometrial cell types in the functionalis layer [1] [2] [3] [4] [5] [6] [7] . However, the source of this stem cell population is unclear.
Although recent in vivo data from human [8] [9] [10] [11] and murine [9, [12] [13] [14] [15] model systems support the concept that the bone marrow is an important contributor of stem cells to the endometrium, these previous studies have several limitations . Human studies that have demonstrated bone marrow-derived endometrial cells in bone marrow transplant recipients are severely limited in the number of subjects examined. Studies that utilize murine bone marrow transplant models have evaluated the extent to which the bone marrow engrafts the endometrium at only one time point posttransplant, ranging from 40 days to 8-12 mo. Moreover, these murine studies do not distinguish glandular from luminal epithelial cells, which are functionally and biochemically distinct epithelial cell types.
In view of the limitations of earlier data, the present study was designed to test the hypothesis that the bone marrow is an important source of nonhematopoietic cells in the multiple endometrial parenchymal cellular compartments (stroma, glandular epithelium, and luminal epithelium) using a wellestablished model of murine bone marrow transplantation. The results demonstrate that the bone marrow is an important source of nonhematopoietic murine endometrial stromal compartment cells and contributes to a much lesser extent to the endometrial glandular and luminal epithelial compartments. These bone marrow-derived cells (BMDCs) may serve as a cellular source for cyclic replenishment of the multiple parenchymal endometrial cell types.
MATERIALS AND METHODS

Animal Models
Two transgenic mouse strains expressing enhanced green fluorescent protein (GFP) were used as bone marrow donors: 1) C57BL/6-Tg(UBC-GFP)30Scha/J, under the control of the human ubiquitin C promoter; and 2) C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ, under the control of the chicken beta-actin promoter (The Jackson Laboratory). Wild-type C57BL/6J female mice (The Jackson Laboratory) were used as recipients of bone marrow transplantation. All animals were housed in the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited Research Animal Facility of New Jersey Medical School under strict barrier conditions. Animals were exposed to a 12L:12D photoperiod, with food and water provided ad libitum. All procedures were performed in compliance with institutional guidelines and were approved by the New Jersey Medical School Institutional Animal Care and Use Committee before initiation. 
Bone Marrow Isolation and Transplantation
Three independent bone marrow transplant experiments, using seven or eight recipient mice per experiment, were performed. Donor bone marrow was flushed from the femurs and tibias of 6-to 9-wk-old male transgenic mice with sterile Medium 199 (Sigma-Aldrich) containing 10% fetal bovine serum (FBS; Gibco, Life Technologies). The bone marrow cell suspension was filtered through sterile, 100-lm mesh strainers (Becton, Dickinson and Company), washed with sterile Medium 199 containing 10% FBS, and resuspended in serum-free Medium 199. Total bone marrow cells were counted using a hemocytometer after lysis of red blood cells using Turk solution (2% acetic acid). Recipient 4-to 6-wk-old female C57BL/6L mice underwent total body irradiation with 900 rads and were transplanted with 1 3 10 7 bone marrow cells by tail vein injection 5-6 h after irradiation.
Determination of Hematopoietic Reconstitution
To determine reconstitution of the hematopoietic system with donorderived, GFP-positive cells, flow cytometry was performed on peripheral blood of all recipient animals. At 7 to 12 wk after bone marrow transplant, blood was taken from the retro-orbital sinus of each recipient mouse. Complete blood cell counts were performed with an automated analyzer (IDEXX RADIL; IDEXX BioResearch). In addition, peripheral blood was subjected to flow cytometry using the FACSCalibur flow cytometer (BD Biosciences) to determine the percentage of peripheral blood cells that were GFP positive.
Vaginal Cytology
After determination of reconstitution of the hematopoietic system with donor-derived bone marrow cells, vaginal cytology was performed to assess estrous cyclicity. A sterile swab was moistened with saline and rotated against the vaginal wall to obtain vaginal cells. Next, 0.1% methylene blue was applied to the slide to aid in visualization of the vaginal cells with the light microscope. These assessments indicated that recipients of bone marrow transplant were not undergoing regular estrous cycles.
Tissue Harvesting
At 3, 5, 9, and 12 mo posttransplant, two to five recipient animals were sacrificed at each time point. Mice were killed by CO 2 inhalation followed by cervical dislocation. The uterus was resected and cleaned under a dissecting microscope to remove adherent fatty tissue. In addition, thymus and tongue were removed for use as positive and negative tissue controls, respectively, in immunohistochemistry studies to detect CD45-positive cells (leukocytes).
For each animal, one uterine horn was fixed in 4% paraformaldehyde for 16-24 h (overnight) at room temperature, dehydrated, and then embedded in paraffin. Sections (section thickness, 6 lm) were cut and mounted on slides. Paraffin-embedded sections were deparaffinized in xylene, rehydrated in graded ethanol washes, and then stained with hematoxylin-and-eosin for assessment of endometrial morphology. The other uterine horn was fixed in 4% paraformaldehyde overnight, then cryoprotected in 30% sucrose for at least 24 h. Tissues were then frozen using liquid nitrogen-cooled isopentane, embedded in ornithine carbamyl transferase (OCT) compound (Sakura), and sectioned (section thickness, 12 lm) on a cryostat.
Confocal Laser Microscopy and Immunofluorescence
The intrinsic fluorescence of GFP-positive cells in uterine paraffinembedded and frozen sections was detected using confocal laser microscopy. For fluorescent imaging of paraffin-embedded uterine tissues, nuclear counterstaining was performed using TO-PRO-3 Iodide (Invitrogen/Life Technologies). Sections were deparaffinized in xylene, rehydrated in a graded series of ethanol washes, and incubated with TO-PRO-3 Iodide (1:300 in PBS) for 15 min at room temperature.
For CD45 staining (pan-leukocyte marker) of uterus and thymus, frozen sections were washed with PBS and then blocked with 1% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 30 min at room temperature. For CD45 staining of tongue, paraffin-embedded sections were deparaffinized in xylene, rehydrated in a graded series of ethanol washes, washed with PBS, and then blocked with 1% BSA in PBS for 30 min at room temperature.
After blocking, uterus, thymus, and tongue sections were incubated with rat anti-mouse CD45 antibody (1:10 dilution in 1% BSA; BD Pharmingen/ BD Biosciences) overnight at 48C. Slides were then washed and incubated with biotinylated goat anti-rat IgG (1:200 dilution in PBS/0.05% Tween 20; Jackson Immunoresearch) for 1 h at room temperature. Slides were again washed and incubated with DyLight 649 Streptavidin (1:100 dilution in PBS; Vector Laboratories) for 1 h at room temperature. Nuclear counterstaining was performed by incubating slides with 4,6-diamidino-2-phenylindole (1:300 dilution in PBS; Invitrogen/Life Technologies) for 5 min at room temperature.
All slides were mounted in VECTASHIELD Mounting Medium (Vector Laboratories) before fluorescent imaging. Imaging was performed at the Confocal Imaging Facility at New Jersey Medical School using a Nikon A1R-MP confocal laser microscope (Nikon Instruments), and images were captured using NIS-Elements software (Nikon Instruments). For quantification of GFPpositive cells and CD45-positive cells in paraffin-embedded and frozen sections, at least four high-power fields from each of three slides per uterine cross-section were assessed. Negative controls excluding primary antibody were included in every staining run. Negative and positive tissue controls for CD45 (tongue and thymus, respectively) were included in every staining run.
Quantitation of Transplanted Cells in Endometrium
For quantitation of GFP-positive cells in the stromal and epithelial cellular compartments, 15 high-power fields (five high-power fields from each of three uterine sections per animal) were assessed for each bone marrow transplant recipient with the exception of one recipient sacrificed at 12 mo, for which 12 high-power fields were assessed. The same high-power fields were used for quantitation in every slide (five high-power fields per slide for each animal with the exception of one animal sacrificed at 12 mo [due to smaller uterine crosssectional area, four high-power fields in each of three slides were assessed from this animal]). For quantitation of GFP-positive cells in the endometrial stromal compartments, the total number of stromal cell nuclei was counted in each high-power field, and the number of GFP-positive cells was then counted and expressed as a percentage of the total stromal cell nuclei counted per animal. At least 1000 stromal cells were counted per animal.
For quantitation of GFP-positive cells in the endometrial glandular and luminal epithelial compartments, 15 high-power fields per recipient animal (five high-power fields from each of three sections per animal) were assessed with the exception of one recipient sacrificed at 12 mo, for which 12 highpower fields were assessed. Because multiple sections were assessed per animal, the total glandular and luminal epithelial area (lm 2 ) was determined for each animal. The total area of GFP-positive cells in the glandular and luminal epithelial compartments was then determined for each animal and expressed as a percentage of the total glandular and luminal epithelial area per animal.
Statistical Analysis
Data were evaluated by nonparametric tests using InStat statistical software (GraphPad Software, Inc.). P-values of less than 0.05 were considered to be significant.
RESULTS
Reconstitution of Bone Marrow
To determine whether the hematopoietic system of recipient mice was successfully reconstituted with GFP-positive donor bone marrow cells (.80% chimerism), flow cytometry of peripheral blood was performed on all bone marrow recipients at 7-17 wk posttransplant. Flow cytometry results are shown in Supplementary Table S1 (available online at www.biolreprod. org).
BMDCs Contribute to Endometrial Cellular Compartments
The proportion of stromal cells derived from the transplanted bone marrow cells (GFP-positive stromal compartment cells) for each animal is shown in Figure 1 The median proportion of stromal cells per uterine section which was bone marrow-derived (GFP-positive) at 9 mo was 22.2% (three uterine sections assessed from each of two animals), significantly greater (P , 0.01) than the median proportion of stromal cells per uterine section which was GFPpositive at 5 mo (6.9%, three uterine cross sections assessed from each of two animals). At 12 mo, the median proportion of stromal cells per uterine section which was GFP-positive was 15.9% (three uterine sections assessed from each of five animals), a result not significantly different (P . 0.05) from that seen at 9 mo.
In distinct contrast to the endometrial stromal compartment, GFP-positive cells were completely undetectable in the endometrial luminal and glandular epithelial compartments at 3 mo and barely detectable at 5 mo (one GFP-positive epithelial cell detected in one of two animals, 15 high power fields analyzed per animal) and 9 mo (one GFP-positive epithelial cell detected in each of two animals, 15 high power fields analyzed per animal) posttransplant. At 12 mo posttransplant, however, a very small but distinct population of GFP-positive cells was detected in both the luminal and glandular epithelium (Figs. 2 and 3) . At 12 mo in experiment 1 (n ¼ 1 animal), 1.1% of the luminal epithelial area and 0.9% of the glandular epithelial area was GFP positive. At 12 mo in experiment 2 (n ¼ 1 animal), 2.7% of the luminal epithelial area and 0.2% of the glandular epithelial area was GFP positive. At 12 mo in experiment 3, the percentage of epithelial area that was GFP positive was 2.1%, 0%, and 0% (n ¼ 3 animals, percentage given for each animal) in the glandular epithelium and 0.2%, 0.2%, and 0% (n ¼ 3 animals, percentage given for each animal) in the luminal epithelium.
BMDCs Give Rise to Nonhematopoietic Cells in the Stromal and Epithelial Compartments
To distinguish bone marrow-derived leukocytes (GFP positive, CD45 positive) from bone marrow-derived nonhematopoietic cells (GFP positive, CD45 negative) in the endometrium, immunohistochemistry using a specific anti-CD45 antibody was performed on frozen sections of uteri from animals sacrificed at 5 and 12 mo posttransplant (Fig. 4) . For each animal, 15 high-power fields were assessed (five highpower fields from each of three uterine sections per animal) with the exception of one animal sacrificed at 12 mo, for which 12 high-power fields were assessed. As shown in Figure 5 , the contribution of the bone marrow to the endometrial stromal compartment increased between 5 and 12 mo posttransplant, attributable to an increase in bone marrow-derived leukocytes at 12 months. The median number of bone marrow-derived stromal leukocytes per uterine section at 12 mo posttransplant was 69.0 (three uterine sections assessed from each of five recipient animals), significantly greater than the median number of bone marrow-derived stromal leukocytes per uterine section at 5 mo (three uterine sections assessed from each of five recipient animals), which was 7.0 (P ¼ 0.0005). However, the data shown in Figure 5 demonstrate that the bone marrow remained a long-term source of nonhematopoietic endometrial stromal compartment cells in all five animals sacrificed at 12 mo posttransplant. The median number of bone marrowderived nonhematopoietic stromal compartment cells per uterine section was 116.5 at 5 mo (three uterine sections assessed from each of two recipient animals), a result not significantly different from the median number of bone marrow-derived nonhematopoietic stromal compartment cells per section at 12 mo posttransplant (three uterine sections assessed from each of five recipient animals), which was 124 The proportion of BMDC which was CD45-negative in each epithelial compartment (glandular vs. luminal) of each animal sacrificed at 12 mo posttransplant is shown in Table 1 . No BMDCs were detected in uterine frozen sections in the glandular or luminal epithelium at 5 mo, consistent with our findings in uterine paraffin-embedded sections at 5 mo.
DISCUSSION
The endometrium is a unique and dynamic tissue that undergoes cyclic regeneration of all cellular compartments with every menstrual cycle. Despite the critical importance of this regenerative process in successful reproduction, the mechanisms that allow cyclic replenishment of all endometrial cell types have not yet been deciphered.
Data from the present study provide new and definitive evidence for the bone marrow as an important source of nonhematopoietic cells in the murine endometrium. Distinct from the few previous murine in vivo studies that support the concept of the bone marrow as a source of endometrial cells [9, [12] [13] [14] [15] , the present study is the first to evaluate engraftment of the endometrium with BMDCs at multiple time points after bone marrow transplant. We followed recipient animals for as long as 12 mo posttransplant to assess long-term engraftment of the uterus with BMDCs. We demonstrate herein that the bone marrow is a source of stromal compartment cells as early as 3 mo posttransplant and that the bone marrow remains a long-term, stable source of nonhematopoietic stromal compartment cells for as long as 12 mo posttransplant. Interestingly, whereas bone marrow-derived epithelial-like cells are virtually undetectable at 3, 5, and 9 mo posttransplant, the bone marrow does contribute to both the glandular and luminal epithelial compartments (albeit in very small numbers) at 12 mo. These data provide important evidence for the bone marrow as an exogenous source of nonhematopoietic cells in multiple endometrial parenchymal cellular compartments, all of which are critical for successful reproduction. Furthermore, these data now raise important questions regarding the timing of recruitment of BMDCs to the endometrium. It remains to be determined whether long-term engraftment with BMDCs is due to ongoing recruitment from the bone marrow or whether the bone marrow seeds the uterus at the time of transplant with mesenchymal and/or hematopoietic stem cells that take up residence in the uterus and serve as progenitor cells over the long term.
The concept that cyclic regeneration of the endometrium is mediated via a resident uterine stem cell population is supported by studies that have identified small populations of endometrial cells exhibiting the properties of stem cells [1, 2, 4] . Putative stem cell populations isolated from human endometrium have been coaxed to differentiate into mature endometrial glandular epithelial, stromal, and endothelial cells both in vitro [3, 5] and in immunodeficient mouse models [5, 7, 16] . These studies, however, did not determine whether these ''resident'' uterine stem cell populations have an extrauterine source, such as the bone marrow. Bone marrow-derived stem cells have been demonstrated to differentiate into mature parenchymal cell types of various nonhematopoietic organs, including liver, skeletal muscle, brain, and skin [17] . More recent data support the bone marrow as a source of various mature endometrial cell types as well.
Several investigators have identified human endometrial stromal, glandular, and/or endothelial cells of donor bone marrow origin in a total of 13 recipients of bone marrow transplant from either human leukocyte antigen (HLA)-mismatched [8] or male [9] [10] [11] donors. These findings are provocative and support the ability of BMDCs to generate endometrial cells de novo. The finding that human bone marrow-derived mesenchymal stem cells can differentiate in vitro into endometrial decidual cells when exposed to 8-bromocyclic adenosine monophosphate (a potent decidualizing agent of human endometrial stromal cells) further supports the bone marrow as a source of endometrial cells [14, 18] .
To date, only three independent laboratories have reported the use of a murine bone marrow transplant model to determine whether BMDCs give rise to endometrial parenchymal cell types. Du and Taylor [12] identified Y chromosome-positive endometrial epithelial and stromal cells in female recipients of bone marrow transplant from male donors at 6 mo posttransplant. These investigators subsequently demonstrated in a male-to-female murine bone marrow transplant model that migration of BMDCs to the endometrium is promoted by ischemic uterine injury [15] and is inhibited by exposure to cigarette smoke [14] . A male-to-female murine transplant ENDOMETRIAL CELLS ARE BONE MARROW-DERIVED model was also used by Mints et al. [9] , who identified endothelial cells of donor origin in recipient endometria at 40 days posttransplant but did not evaluate whether other endometrial cell types were donor-derived. Brantincsák et al. [13] created a transgenic mouse model in which all CD45-positive cells coexpressed GFP and demonstrated that CD45-positive hematopoietic progenitor cells contributed to uterine epithelium. Collectively, these data support the hypothesis that the bone marrow is an important source of endometrial stem cells, exhibiting the capacity to differentiate into parenchymal and endothelial cell types. However, only one study [13] evaluated engraftment of the uterus at a time period as long as 12 mo posttransplant. In these studies, failure to evaluate recipient endometrium over the long-term (i.e., 1 yr posttransplant) may have led to an underestimation of the bone marrow's contribution to the endometrial parenchymal and endothelial compartments and thus represents a major limitation.
In the current protocol, lethal-dose irradiation before bone marrow transplant appeared to ablate estrous cyclicity in recipient animals, as documented by daily vaginal cytology (data not shown). Despite the absence of estrous cycles, all but one recipient animal showed evidence of vaginal estrogen action at the time of hysterectomy. Therefore, in the present study, recruitment of BMDCs to the endometrium cannot be interpreted as being estrogen-independent. Now that it is clear the bone marrow is a source of nonhematopoietic endometrial cells, further studies are necessary to determine the mechanisms responsible, including whether ovarian steroid hormones regulate engraftment of the endometrium with BMDCs.
In summary, using a murine bone marrow transplant model, we have demonstrated that the bone marrow is a significant source of nonhematopoietic cells in multiple cellular compartments of the endometrium: stroma, glandular epithelium, and luminal epithelium. Our findings in murine endometrium resemble results from reports describing long-term engraftment of human endometrium with BMDCs [8, 10, 11] , which suggests translational potential of our model. Each cellular compartment, which must regenerate in its entirety with every menstrual cycle, plays an essential role in the establishment of pregnancy. Determining the source of regenerative endometrium is critical in advancing our understanding of the mechanisms responsible for endometrial regeneration and decidualization. Defects in endometrial growth and function contribute to diseases such as Asherman syndrome (intrauterine adhesions) and implantation failure, both of which are significant causes of infertility.
This newly discovered contribution of BMDCs to critical structural components of the endometrium suggests their use in the treatment of such disorders of endometrial function. It is also possible that the bone marrow is a source of endometrial cells in proliferative disorders of endometrium, such as endometriosis, endometrial hyperplasia, and endometrial cancer. The specific bone marrow stem cell type (mesenchymal stem cells and/or hematopoietic stem cells) that gives rise to mature endometrial parenchymal cells as well as the mechanisms that regulate recruitment and differentiation of BMDCs into mature endometrial cell types remain to be determined.
